A Phase 3 interventional study of Budesonide and Fluticasone propionate in Seasonal Allergic Rhinitis, sponsored by AstraZeneca. Completed. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Rhinitis, Allergic, Seasonal by AstraZeneca — none open to participants now, none under way, none of them phase 3. Rhinitis, Allergic, Seasonal · AstraZeneca.
Among the 14 studies in Rhinitis, Allergic, Seasonal by AstraZeneca, this one has the largest planned enrollment, is one of 3 that started in 2003, is one of 12 in phase 3, and was the 7th registered.
404 studies on the registry are indexed under Rhinitis, Allergic, Seasonal; 24 are open to participants now.
Browse Rhinitis, Allergic, Seasonal studies →None of the 14 studies in Rhinitis, Allergic, Seasonal by AstraZeneca is open now. The open studies under Rhinitis, Allergic, Seasonal, anywhere →
Of the 17 Rhinitis, Allergic, Seasonal studies recruiting now, 2 (12%) set no upper age limit and 15 (88%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 131 across 366 interventional studies indexed under Rhinitis, Allergic, Seasonal.
Median enrollment 450 across the 14 interventional studies. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Rhinitis, Allergic, Seasonal by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare once daily treatment with Rhinocort against placebo and Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
is a candidate for treatment with nasal based on a history of either
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Budesonide
Drug: Budesonide
Fluticasone propionate
Drug: Fluticasone propionate
Drug: Placebo
Also known as: Rhinocort AQUA
Also known as: Flonase®
To compare once daily treatment with Rhinocort against placebo and at reliving the nasal symptoms of seasonal allergic rhinitis.
Time frame: 2 weeks
To compare once daily treatment with Rhinocort against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
Time frame: 2 weeks
To compare once daily treatment with placebo against Fluticasone Propionate at reliving the nasal symptoms of seasonal allergic rhinitis.
Time frame: 2 weeks
Safety assessment via adverse events and clinical measurements.
Time frame: 2 & 4 weeks
No study locations are listed for this record.
The record gives a start of Apr 2003, a primary completion of Jul 2003 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Budesonide
Rhinitis, Allergic, Seasonal →